Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 29, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 17, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 10, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
September 03, 2025 09:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
July 09, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 25, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 24, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 10, 2025 09:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
May 28, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...